Beyond hydrophilicity: repositioning SLActive for 5 straight years of share growth

Ten years after launch, SLActive's growth had stalled for 3 years running. Its original differentiator — hydrophilicity — had become table stakes: lower-priced competitors now offered hydrophilic surfaces and made the same claims, without the clinical investment behind them.

VoC research surfaced the real insight: clinicians weren't buying hydrophilicity, a technical feature — they were buying confidence in successful outcomes when a patient, procedure or protocol carried more risk. Repositioned SLActive entirely around clinical performance, not surface chemistry, and built a flexible "Performance USPs" sales framework around three areas competitors couldn't match: immediate loading, compromised patients, and bone regeneration — each backed by evidence unique to SLActive (e.g. 98.2% survival at 10 years in immediate loading, a randomized controlled multicenter trial). Turned that framework into a sales battle card with competitor-specific guidance and talk tracks — giving reps a ready answer in the conversations they found hardest, and it became one of the most used sales aids in the field. Went further than messaging: pushed Clinical, Med Affairs and RA through an FDA label change, removing irradiated and diabetic patients from Cautions/Contraindications — making SLActive the only implant with FDA-approved performance claims in those patient groups, a clinical fact competitors couldn't replicate. Rolled the new positioning out globally across 40+ countries and ~15 languages, training 35 sales teams at basic level and 20 at advanced.

SLActive's share of the implant portfolio grew against the less expensive SLA for 5 consecutive years, 2016 through 2020 — not ordinary unit growth from an expanding portfolio, but a genuine, sustained shift in product-mix preference, driven as much by rep confidence in the field as by the evidence itself.